newsfilter
← Latest News
GlobeNewswire·

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients –– – Topline 56-week